Long COVID-19 Neuropeptide and Cytokine Expression Data

90 patients were studied, with 60% male and 40% female participants. The dataset contains experimental measurements of upregulated cytokines IL-6 and IL-10, and neuropeptide Substance P (SP), from symptomatic and asymptomatic long COVID-19 groups. It includes patient demographic data, symptom persistence durations, and results from computational drug screening against the NK1R receptor.

Use Cases

• Correlate symptom severity categories with IL-6, IL-10, and SP expression levels across patient groups.
• Analyze demographic variables like age and gender against reported symptom frequencies such as fatigue, headache, and anxiety.
• Use computational docking scores (e.g., -9.3 kcal/mol for aprepitant) to model drug-receptor interactions for NK1R.
• Compare symptom persistence duration (e.g., 19 ± 6 weeks) with cytokine upregulation data to identify progression markers.

Strengths

• Includes experimental biomarker data (IL-6, IL-10, SP) for 90 patients with quantified expression differences.
• Provides detailed patient demographics and symptom statistics, such as 48% reporting fatigue and 28% with anxiety.
• Contains results from virtual drug screening with specific molecular dynamics metrics like RMSD and binding affinity.

Limitations

• Small sample size of 90 patients limits statistical power and generalizability of findings.
• Dataset scope is limited to a specific research study; it is not a large-scale clinical repository.
• The 9.0 KB file size indicates a summary or processed data table, not raw, high-volume experimental data.

Provenance

Source

Muhammad Abdullah via figshare.

Collection Method

Data collected from patient blood samples via ELISA and RT-qPCR, with subjects screened in an outpatient clinic. Computational drug screening performed via virtual docking.

Time Range

Study period not specified; data reflects patient assessments during the long COVID-19 condition.

Freshness

Last updated March 2026.

Geography

null